Kareus Therapeutics SA has entered a broad strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials. Quintiles will make an undisclosed investment in Kareus through an equity investment and access to clinical service on a shared-risk basis. Kareus plans to submit an IND application for KU-046, a new chemical entity for the treatment of Alzheimer’s disease. Kareus has also identified a lead series of molecules for the treatment o...